TScan Therapeutics Files 8-K Report

Ticker: TCRX · Form: 8-K · Filed: 2024-04-16T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-K

TL;DR

TScan Therapeutics filed an 8-K, mostly boilerplate for now.

AI Summary

On April 16, 2024, TScan Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements, with no specific material events or financial figures detailed in the provided excerpt. The company is incorporated in Delaware and headquartered in Waltham, Massachusetts.

Why It Matters

This 8-K filing indicates that TScan Therapeutics, Inc. is providing updates or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and operational status.

Risk Assessment

Risk Level: low — The provided excerpt of the 8-K filing does not contain specific material events or financial data that would indicate a high or medium risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for TScan Therapeutics, Inc.?

The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating disclosures related to 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.

When was this 8-K report filed?

The report was filed on April 16, 2024.

What is TScan Therapeutics, Inc.'s state of incorporation?

TScan Therapeutics, Inc. is incorporated in Delaware.

Where are TScan Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 830 Winter Street, Waltham, Massachusetts, 02451.

Does the filing excerpt provide specific financial details or material events?

No, the provided excerpt of the 8-K filing does not detail specific financial figures or material events, focusing instead on the form type and company identification.

From the Filing

0001193125-24-097764.txt : 20240416 0001193125-24-097764.hdr.sgml : 20240416 20240416161609 ACCESSION NUMBER: 0001193125-24-097764 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20240416 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24848018 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d820546d8k.htm 8-K 8-K false 0001783328 0001783328 2024-04-16 2024-04-16     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2024     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   830 Winter Street , Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (857) 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trade Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 7.01 Regulation FD Disclosure. On April 16, 2024, TScan Therapeutics, Inc. (the “Company”) issued a press release to provide an update on its solid tumor and heme malignancies clinical programs. The Company also released an updated company presentation, which includes, among others, additional details of its solid tumor and heme malignancies clinical programs. Copies of the press release and the updated company presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K. The updated company presentation will also be available in the investor relations section of the Company’s website at https://

View on Read The Filing